Form 4: Abbott Laboratories Director Robert J. Alpern Reports Acquisition of Stock Equivalent Units

Director Robert J. Alpern reports acquisition of 69 stock equivalent units in Abbott Laboratories on December 31, 2024, through director fees credited to a grantor trust.

Summary

• Robert J. Alpern, a director of Abbott Laboratories, reported acquiring 69 stock equivalent units on December 31, 2024.
• These units were obtained through director fees credited to a stock equivalent unit account under a grantor trust.
• The stock equivalent units earn the same return as if the fees were invested in Abbott shares and are generally paid in cash at age 65 or upon retirement from the board.
• The price of the stock equivalent units was $113.11.
• Following the transaction, Alpern beneficially owns 9,988 stock equivalent units.
• The report was filed on January 3, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director increasing their stake in the company, indicating confidence. However, it's a routine transaction.

Industry Context

This filing is a routine disclosure of a director's acquisition of stock equivalent units, which is a common form of compensation for board members. It reflects the director's alignment with the company's long-term performance.

Stakeholder Impact

• The transaction signals to shareholders that a director is increasing their alignment with the company's performance.

Key Dates